The potency of opioid pain relievers comes at a cost. Side effects range from increased tolerance to addiction to gastrointestinal (GI) symptoms to breathing problems. Researchers have therefore long sought ways to separate the effectiveness of opioid therapies from their adverse effects.
A newly developed molecule could offer a path to more tailored yet potent pain relief. Recently described in Cell, the molecule binds to opioid receptors and can be switched on and off with light. In mice, the approach reduced signs of both acute and chronic pain and had fewer side effects than morphine.
Paper coauthor Dirk Trauner, a chemist at the University of Pennsylvania in Philadelphia, whose lab led the synthesis of the molecule, says that opioids are “indispensable” as powerful pain relievers. This approach, he says, could help minimize their side effects and make them safer.
In collaboration with Josh Levitz, a neuroscientist and biophysicist at Weill Cornell Medicine in New York City, Trauner aimed to develop a version of an opioid containing a molecular switch known as an azobenzene, which takes on different configurations when exposed to different wavelengths of light. They thought that, when attached to the right molecule, the switch might give them control over the mu-opioid receptor, the primary target of opioid pain relievers.
Trauner’s lab developed a library of azobenzenes and studied their structure with researchers at the University of Southern California led by Cornelius Gati and Vsevolod Katritch. One molecule, called AM-3, showed the behavior they were looking for. When bound to the opioid receptor in cells and hit with UV light, the molecule caused structural changes in the receptor that activated signaling. When hit with lower-energy light, the molecule returned to its more neutral state and stopped activating the receptor.
In Levitz’s lab, mice with an injection of AM-3 that was exposed to UV light responded more slowly to heat—a classic test of pain sensitivity in animals—than those given the version without light. Using UV light to illuminate entire animals that were injected with AM-3 produced a similar effect, as did illuminating just the paw that had been injected, suggesting that the molecule could be turned on and off locally and in the animal. And unlike mice treated with morphine, those that had received pre-activated AM-3 did not show impaired breathing or hyperactivity, which would be signs that the molecule had accumulated in the central nervous system.
Levitz says that one approach for avoiding side effects is to design opioids that stay in the body’s periphery rather than reaching the brain, which is where opioid receptors can drive processes that suppress breathing, for example. But opioid receptors outside the brain also cause side effects, such as GI problems.
“By shining light, we can go one step further than merely restricting it to the periphery,” Levitz says. “We can actually restrict it to the part of the periphery where the pain is originating.”
When they selectively illuminated the site of pain in the paw, they detected no constipation in the mice. Although AM-3 does not reach the brain if injected systemically, the researchers also injected it into the brains of mice and observed signs of reduced pain when they used fiber-optic cables inserted into their skulls to illuminate a region involved in opioid-driven pain relief. AM-3 also reduced signs of pain in models related to cancer and nerve injury.
Future experiments could help determine whether this approach will work in the long term without increasing tolerance to the drug, says Steve Davidson, a pain neurobiologist and associate director of the Pain Research Center at New York University, who was not involved in the study. In the meantime, he calls it “a really powerful tool that can be used tomorrow, in some of these studies, to explore how the opioid system works to create more specific and safer opioids.” The approach could, for example, help researchers better understand how opioids suppress breathing, Davidson notes, or how the reward and pain-relieving parts of the opioid system work independently. “I think it’ll be a real game-changer,” he says.
Next, the researchers plan to develop a version of the compound that can be activated by wavelengths of light that are safer than UV—needed for this kind of classical azobenzene, Trauner says—and better able to penetrate tissue in humans, such as red light. Levitz says that he hopes the work also lays the foundation for treating other diseases where localized therapeutics could help, including neurological and metabolic conditions.
“The idea that, really, photopharmacology can be a new wave of drug treatment, with pain as the front-line application,” Levitz says. “I think that’s what’s most exciting.”